Geranylgeranylacetone protects against morphine-induced hepatic and renal damage in mice

Fu-Cheng Luo1, Lu Zhao, Juan Deng

  • 1Medical Faculty, Kunming University of Science and Technology, Kunming 650500, P.R. China.

Molecular Medicine Reports
|December 12, 2012
PubMed

Insights

Geranylgeranylacetone (GGA) protects against morphine-induced liver and kidney damage by reducing apoptosis and oxidative stress. GGA enhances protective proteins thioredoxin-1 (Trx-1) and heat shock protein 70 (Hsp70).

Area of Science:

  • Pharmacology
  • Toxicology
  • Cell Biology

Background:

  • Opioid drugs, like morphine, can cause liver and kidney damage through oxidative stress and apoptosis.
  • Thioredoxin-1 (Trx-1) and heat shock protein 70 (Hsp70) are key cellular protectors against various toxins.
  • Geranylgeranylacetone (GGA) is known to induce Trx-1 and Hsp70 expression.

Purpose of the Study:

  • To investigate the protective effects of GGA against morphine-induced hepatic and renal damage.
  • To determine if GGA modulates apoptosis pathways and oxidative stress markers.
  • To examine GGA's influence on Trx-1 and Hsp70 expression in the context of morphine toxicity.

Main Methods:

  • Morphine was administered to induce liver and kidney damage.
  • Pre-treatment with GGA was used to assess its protective potential.
  • Apoptosis pathways (mitochondria-mediated and ER-mediated) were analyzed.
  • Levels of malondialdehyde (MDA), a marker of oxidative damage, were measured.
  • Expression of Trx-1 and Hsp70 was quantified.

Main Results:

  • Morphine induced liver and kidney apoptosis via the mitochondria-mediated pathway.
  • GGA pre-treatment attenuated the activation of caspases-9 and -3, key apoptotic enzymes.
  • GGA suppressed the increase in malondialdehyde (MDA) levels caused by morphine.
  • GGA enhanced the expression of Trx-1 and Hsp70 in response to morphine exposure.

Conclusions:

  • GGA demonstrates protective effects against morphine-induced hepatic and renal damage.
  • The protective mechanism involves the inhibition of apoptosis and oxidative stress.
  • GGA's ability to induce Trx-1 and Hsp70 contributes to its therapeutic potential.
  • GGA may serve as a novel therapeutic agent for opioid-induced organ damage.

Related Concept Videos

Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...